Research Article

The study of prevalence of hyperuricemia and metabolic syndrome in type 2 diabetes mellitus

Sanjay A. Mundhe*, Dinkar R. Mhasde

Department of General Medicine, B. J. Medical College, Pune, Maharashtra, India

Received: 12 February 2016
Accepted: 01 March 2016

*Correspondence:
Dr. Sanjay A. Mundhe,
E-mail: drsanjaymundhe@gmail.com

ABSTRACT

Background: Type 2 diabetes mellitus (Type 2 DM) is associated with cardiovascular complications, of which metabolic syndrome plays a prominent role. The metabolic syndrome is a cluster of cardiovascular risk factors characterized by central obesity, insulin resistance, dyslipidemia and hypertension. Hyperuricemia is gaining importance as cardiovascular risk factor and has role in renal and metabolic diseases. Our study was aimed to find out the prevalence of hyperuricemia and metabolic syndrome in type 2 DM and to evaluate association of hyperuricemia with metabolic syndrome.

Methods: This observational longitudinal study was carried out on 150 patients of type 2 DM patients for determination of hyperuricemia and components of metabolic syndrome.

Results: Metabolic syndrome was diagnosed in 68 patients (45.3%) with higher prevalence in males (53.4%) than females (33.9%). Hyperuricemia was found in 38 patients (25.3%) with higher prevalence in males (33%) than females (14.5%). Hyperuricemia and metabolic syndrome was found in 32 (21.3%) patients with higher prevalence among males (27.3%) than females (12.9%). The patients with hyperuricemia and metabolic syndrome compared to those without hyperuricemia and metabolic syndrome had higher mean age (63.16 versus 55), mean FBS (139.31 versus 117.23), mean duration of diabetes (12.66 versus 5.64), mean BMI (28.71 versus 24.61), systolic BP (128.50 versus 122.12), diastolic BP (80.63 versus 74.27), TG (176.28 versus 141.69) and lower HDL (39.63 versus 52.03).

Conclusions: Prevalence of hyperuricemia is higher in patients of type 2 diabetes with metabolic syndrome and is positively correlated with BMI, blood pressure and triglycerides and negatively correlated with HDL-C.

Keywords: Atherogenic dyslipidemia, Cardiovascular risk, Central obesity, Hypertension, Hyperuricemia, Metabolic syndrome, Type 2 diabetes mellitus

INTRODUCTION

Type 2 diabetes mellitus (type 2 DM) is associated with cardiovascular complications, of which metabolic syndrome (Mets) plays a prominent role. The metabolic syndrome is a cluster of cardiovascular risk factors that is characterized by central obesity, insulin resistance, dyslipidemia and hypertension.1 Hyperuricemia or elevated serum uric acid levels (SUA) is a biochemical entity that is gaining increasing importance as it is found by some researchers to be not only a cardiovascular risk factor but also plays a role in development of renal and metabolic diseases.2-4 Some reports on SUA and metabolic syndrome have noted that increased SUA concentration is associated with increased prevalence of some of the parameters of the metabolic syndrome like obesity, dyslipidemia and hypertension.5,6 In these reports, the documented prevalence rates of hyperuricemia ranged from 13-19% with greater proportions of males having elevated levels of SUA compared to females.5,6 Although SUA levels are usually higher in males than females, there is an increase in SUA
levels in both sexes with increasing age. Available reports on hyperuricemia from sub-Saharan Africa showed that hyperuricemia was found to be associated with increased cardio-metabolic risk.\textsuperscript{7,8} The aim of our study was to find out the prevalence of hyperuricemia and metabolic syndrome in type 2 DM and also to evaluate possible association of hyperuricemia with metabolic syndrome. Thus, we hope to document the scope of hyperuricemia and also describe the phenotype of cardiovascular risk factors of metabolic syndrome in patients of type 2 diabetes mellitus in Indian population.

**METHODS**

**Study population**

150 diagnosed patients of type 2 diabetes mellitus attending the outpatient department or admitted to medicine wards of a tertiary care hospital over a period of 1 year.

**Inclusion criteria**

Consecutive patients of diagnosed type 2 diabetes mellitus attending the outpatient department or admitted to medicine wards of a tertiary care hospital.

**Exclusion criteria**

- Pregnancy; Patients on Thiazides, O.C. pills, A.K.T drugs, Cytotoxic drugs, salicylate xanthine oxidase inhibitors or uricosuric drugs, lymphoma, leukaemia, nephrotic syndrome, alcoholics, smokers, organ transplantation and age below 30 years

**Study design**

This observational longitudinal study was carried out in medicine department of tertiary care hospital. In this study, 150 patients of already diagnosed type 2 diabetes mellitus who fulfilled the inclusion and exclusion criteria and who gave a written informed consent were considered for study. Patients were interviewed as per performa with appropriate history, physical examination and necessary investigations.

All patients were studied with the following parameters:

- Physical examinations.
- Anthropometry- weight, height, BMI and waist circumference.
- Blood parameters- lipids, renal and liver function tests, serum uric acid level, complete blood count and blood sugar levels.
- Imaging like X-ray chest, electrocardiography and ultrasonography of abdomen whenever required.

**Method of data collection**

Prior informed written consent was taken before evaluating each patient and detailed history was obtained from patients. Physical examination was done and blood pressure measurements were recorded. Blood pressure was recorded in the lying position in the right arm after rest with a mercury sphygmomanometer. Two readings were taken 5 minutes apart and the mean of the two was recorded as the blood pressure. Anthropometric measurements including height, weight, BMI, waist circumference and hip circumference were measured by height scale, weighing machine and inch tape respectively. All the female patients were examined in presence of a female attendant.

**Anthropometric measurements**

*Height*: Height was measured by fixing a tape measure to a wall and measuring the height with a movable headboard, with measures to the nearest centimetre. Patients were asked to stand upright without shoes, with their back against the wall, heels together and eyes directed forward.

*Weight*: Weight was measured with a weighing machine after asking patients to wear light clothing and weight was recorded to the nearest 0.5 kg.

*Waist circumference*: Waist circumference was measured using a non-stretchable measuring tape. Patients were asked to stand erect in a relaxed position with both feet together. One layer of light clothing was accepted. Waist circumference was measured at the midpoint between the iliac crest and the lower margin of the ribs. Waist circumference was measured to the nearest centimetre.

**Definitions**

**Metabolic syndrome**

According to the IDF definition for a person to be defined as having metabolic syndrome, must have:\textsuperscript{9}

- Central obesity (waist circumference more than for men and 80 cm for women, plus any two of the following four factors.
- *Raised TG level*: More than 150 mg/dL, or specific treatment for this lipid abnormality.
- *Reduced HDL cholesterol*: Less than <40 mg/dL in males and <50 mg/dL in females, or specific treatment for this lipid abnormality.
- *Raised blood pressure*: More than Systolic BP 130 or diastolic BP 85 mm Hg, or treatment of previously diagnosed hypertension.
- *Raised fasting plasma glucose (FPG)*: More than 100 mg/dL or previously diagnosed type 2 diabetes.
Hyperuricemia

Patients having serum uric acid levels more than 7 mg% in males and more than 6 mg% in females.

Biochemical analysis

Blood samples collected in the clinical biochemistry laboratory were used for in vitro biochemical analysis. All the samples were collected by standard procedures under aseptic conditions. Standard procedures were followed for the preservation and storage of samples before analysis. Total cholesterol was determined enzymatically using an ERBA test kit (CHOD/PAP method). Similarly HDL-cholesterol (direct enzymatic method), triglyceride (GPO/PAP method) and uric acid (uricase/POD method) levels was measured using standard auto analyser. The values of LDL-cholesterol and VLDL-cholesterol and the risk ratio was calculated using Friedwald formula. Internal quality control for the laboratory determinations was regularly performed.

Statistical analysis

Statistical analysis was performed using SPSS version 13.0 software. Categorical variables are expressed as percentages. Comparisons between quantitative data were conducted using independent-sample t-tests and categorical variables were analysed using chi-square tests. Data are presented as odds ratios (OR) with 95% confidence intervals (CI). A value of p<0.05 was considered statistically significant.

RESULTS

During the study period, 150 patients of already diagnosed type 2 diabetes mellitus who fulfilled the inclusion and exclusion criteria were enrolled in study. Subjects enrolled for the study were in age group of 30 to 84 years. The largest numbers of subjects; 51 (34%) were in the age group of 51-60 years and lowest 13 (8.67%) and 14 (9.33%) from age more than 71 years and less than 40 years respectively (Table 1).

Table 1: Age distribution of subjects studied.

| Age group (years) | Male | Female | Total |
|-------------------|------|--------|-------|
| <40               | 7    | 7      | 14 (9.33%) |
| 41-50             | 24   | 21     | 45 (30%)   |
| 51-60             | 34   | 17     | 51 (34%)   |
| 61-70             | 16   | 11     | 27 (18%)   |
| >71               | 8    | 6      | 13 (8.67%) |
| Total             | 88   | 62     | 150 (100%) |

Out of these, 88 were males (58.67%) and 62 (41.33%) were females (Table 2).

Table 2: Sex distribution of subjects studied.

| Sex       | Number | Percentage (%) |
|-----------|--------|----------------|
| Female    | 62     | 41.33%         |
| Male      | 88     | 58.67%         |
| Total     | 150    | 100.0%         |

Table 3: Sex-wise distribution of different variables among the study population.

| Variables                        | Female Mean | Female SD | Female Median | Female IQR | Male Mean | Male SD | Male Median | Male IQR | t-Value | P-Value  | Difference |
|----------------------------------|-------------|-----------|---------------|------------|-----------|---------|-------------|----------|----------|----------|------------|
| Age (years)                      | 56.29       | 9.35      | 56.08         | 15.50      | 57.06     | 9.27    | 57.00       | 15.50    | -0.546   | 0.585    | Not Significant |
| FBS (mg%)                        | 120.6       | 27.05     | 116.00        | 32.25      | 122.8     | 26.71   | 119.00      | 31.75    | -0.796   | 0.426    | Not significant |
| Duration of DM (years)           | 6.29        | 5.31      | 4.00          | 8.00       | 7.73      | 5.15    | 8.00        | 8.00     | -1.897   | 0.058    | Not significant |
| BMI (KG/M²)                      | 25.00       | 2.01      | 24.87         | 2.77       | 25.83     | 2.73    | 25.33       | 4.93     | -1.632   | 0.103    | Not significant |
| Systolic BP (mmHg)               | 122.4       | 11.37     | 120.00        | 10.00      | 124.2     | 14.32   | 120.00      | 20.00    | -0.615   | 0.539    | Not significant |
| Diastolic BP (mmHg)              | 74.77       | 6.96      | 70.00         | 10.00      | 76.23     | 8.23    | 80.00       | 10.00    | -1.217   | 0.224    | Not significant |
| Serum uric acid (mg%)            | 4.10        | 1.47      | 3.95          | 2.35       | 5.70      | 1.65    | 6.10        | 2.50     | -5.534   | <0.0001  | Significant |
| HDL-C (mg%)                      | 54.31       | 5.61      | 54.50         | 5.00       | 45.91     | 9.18    | 45.00       | 15.00    | -5.747   | <0.0001  | Significant |
| TG (mg%)                         | 139.8       | 23.10     | 135.00        | 32.50      | 155.5     | 27.84   | 164.50      | 50.75    | -3.306   | 0.00095  | Significant |
Table 4: Sex distribution of metabolic syndrome.

| Metabolic syndrome | Sex | Total |
|--------------------|-----|-------|
|                    | Female | Male |       |
| Yes                | 21     | 47   | 68    |
| No                 | 41     | 41   | 82    |
| Total              | 62     | 88   | 150   |

Chi-square tests

| Value | df | p-value | Association |
|-------|----|---------|-------------|
| 5.603 | 1  | 0.018   | Significant |

Risk estimate

| Value | 95% Confidence interval |
|-------|-------------------------|
|       | Lower | Upper |

Odds ratio for metabolic syndrome (Yes / No )

| Value | 95% Confidence interval |
|-------|-------------------------|
| 0.447 | 0.228 | 0.875 |

For cohort sex = Female

| Value | 95% Confidence interval |
|-------|-------------------------|
| 0.618 | 0.407 | 0.937 |

For cohort sex = Male

| Value | 95% Confidence interval |
|-------|-------------------------|
| 1.382 | 1.057 | 1.808 |

The distribution of variables like age, fasting blood sugar, duration of diabetes, BMI and blood pressure in study population was similar in both males and females and the difference observed is not statistically significant (p>0.05). However males had higher values of variables like serum uric acid and TG while values of HDL-C were higher in females and these differences are statistically significant (p<0.05) (Table 3).

Metabolic syndrome was diagnosed in 68 patients (45.3%) with the prevalence of metabolic syndrome in males (53.4%) being more than females (33.9%) and the difference is statistically significant (p<0.05) (Table 4).

Out of 72 subjects with duration of diabetes <5 years, only 15 (20.83%) had metabolic syndrome, whereas 20 (86.96%) out of 23 and 13 (86.67%) out of 15 with duration of 11-15 years and >16 years respectively had metabolic syndrome (Table 5).

Hyperuricemia was found in 38 patients (25.3%) with the prevalence of hyperuricemia in males (33%) being more than females (14.5%) and this difference is statistically significant (p<0.05) (Table 6).

Out of the 150 subjects, 32 (21.3%) had hyperuricemia with metabolic syndrome and among these subjects having hyperuricemia and metabolic syndrome, 24 were males and 8 were females. The prevalence among male of hyperuricemia and metabolic syndrome together was more (27.3%) than females (12.9%) and this difference is statistically significant (p<0.05) (Table 7).

Table 5: Duration of diabetes and metabolic syndrome.

| Duration of diabetes (years) | Cases with metabolic syndrome | Cases without metabolic syndrome | Total |
|------------------------------|--------------------------------|---------------------------------|-------|
| 5                            | 15 (20.83%)                    | 57 (79.17%)                     | 72 (100%) |
| 6-10                         | 20 (50%)                       | 20 (50%)                        | 40 (100%) |
| 11-15                        | 20 (86.96%)                    | 03 (13.04%)                     | 23 (100%) |
| >16                          | 13 (86.67%)                    | 02 (13.33%)                     | 15 (100%) |

Table 6: Sex distribution of hyperuricemia.

| Hyperuricemia | Sex | Total |
|---------------|-----|-------|
|               | Female | Male |       |
| Yes           | 9     | 29    | 38    |
| No            | 53    | 59    | 112   |
| Total         | 62    | 88    | 150   |

Chi-Square tests

| Value | df | p-value | Association |
|-------|----|---------|-------------|
| 6.537 | 1  | 0.011   | Significant |

Risk Estimate

| Value | 95%Confidence interval |
|-------|-------------------------|
|       | Lower | Upper |

Odds Ratio for Hyperuricemia(Yes / No )

| Value | 95%Confidence interval |
|-------|-------------------------|
| 0.345 | 0.15 | 0.796 |

For cohort Sex = Female

| Value | 95%Confidence interval |
|-------|-------------------------|
| 0.5   | 0.274 | 0.915 |

For cohort Sex = Male

| Value | 95%Confidence interval |
|-------|-------------------------|
| 1.449 | 1.129 | 1.859 |

Among the study subjects, out of 38 patients having hyperuricemia; 35 patients also had high triglyceride levels and only 3 patients of hyperuricemia had normal levels of triglyceride and this difference is statistically significant (p<0.05) (Table 8).
Out of 38 patients having hyperuricemia; 29 patients also had hypertension and 9 patients among non-hypertensive had hyperuricemia and this difference is statistically significant (p<0.05) (Table 9).

**Table 7: Sex distribution of hyperuricemia with metabolic syndrome.**

| Metabolic syndrome with hyperuricemia | Sex          | Total |
|--------------------------------------|--------------|-------|
|                                      | Female | Male |       |
| Yes                                  | 8      | 24   | 32    |
| No                                   | 54     | 64   | 118   |
| Total                                | 62     | 88   | 150   |
| Chi-Square tests                     | Value  | df   | p-value | Association |
| Pearson Chi-Square                   | 4.475  | 1    | 0.034  | Significant |
| Risk estimate                        | Value  | 95% Confidence interval |
| Odd ratio for metabolic syndrome and hyperuricemia | Value  | df   | p-value | Association |
| For cohort Sex = Female              | 0.3951 | 0.1641 | 0.9508 |
| For cohort Sex = Male                | 0.5463 | 0.2361 | 1.2642 |
|                                       | 1.3828 | 0.751 | 2.5462 |

**Table 8: Relation between hyperuricemia and triglyceride.**

| Hyperuricemia | TG          | Total |
|---------------|-------------|-------|
|               | High | Normal |       |
| Yes            | 35    | 3      | 38    |
| No             | 37    | 75     | 112   |
| Total          | 72    | 78     | 150   |
| Chi-Square tests | Value  | df   | p-value | Association |
| Pearson Chi-Square | 39.664 | 1    | < 0.0001 | Significant |
| Risk Estimate  | Value  | 95 % Confidence interval |
| Odds Ratio for hyperuricemia (Yes / No) | 23.649 | 6.822 | 81.974 |
| For cohort TG = High                | 2.788 | 2.108 | 3.688 |
| For cohort TG = Normal               | 0.118 | 0.039 | 0.352 |

**Table 9: Relation between hyperuricemia and hypertension.**

| Hyperuricemia | Hypertension | Total |
|---------------|--------------|-------|
|               | Yes  | No       |       |
| Yes           | 29    | 9       | 38    |
| No            | 51    | 61      | 112   |
| Total         | 80    | 70      | 150   |
| Chi-Square tests | Value  | df   | p-value | Association |
| Pearson Chi-Square | 10.801 | 1    | 0.001  | Significant |
| Risk Estimate  | Value  | 95% Confidence interval |
| Odds Ratio for Hyperuricemia (Yes / No) | 3.854 | 1.672 | 8.885 |
| For cohort Hypertension = Yes            | 1.676 | 1.281 | 2.193 |
| For cohort Hypertension = No              | 0.435 | 0.24  | 0.789 |

Out of 38 patients having hyperuricemia; 26 patients also had low HDL-C and only 12 patients among normal HDL-C had hyperuricemia and this difference is statistically significant (p<0.05) (Table 10).
The patients with hyperuricemia compared to patients having normal uric acid levels had higher mean age (63.42 versus 54.47), higher mean FBS (136.5 versus 117), higher mean duration of diabetes (11.55 versus 5.63), higher mean BMI (27.97 versus 24.64), higher systolic BP (128.58 versus 121.75), higher diastolic BP (80.16 versus 74.09), higher TG (174 versus 140.6) and lower HDL (40.47 versus 52.4) and these differences are statistically significant for all the variables (p<0.05) (Table 11).

### Table 10: Relation between hyperuricemia and HDL-C.

| Hyperuricemia | HDL-C Low | HDL-C Normal | Total |
|---------------|-----------|--------------|-------|
| Yes           | Number 26 | 12           | 38    |
| No            | Number 9  | 103          | 112   |
| Total         | Number 35 | 115          | 150   |

### Table 11: Comparison of various variables between cases with and without hyperuricemia.

| Variables         | Hyperuricemia present | Hyperuricemia absent | Unpaired t-test applied |
|-------------------|------------------------|----------------------|-------------------------|
|                   | Mean | SD   | Median | IQR  | Mean | SD   | Median | IQR  | t-value | p-value | Difference |
| Age (years)       | 63.42 | 8.26   | 64.50 | 11.25 | 54.47 | 8.50 | 53.00 | 11.75 | -5.17   | <0.0001 | Significant |
| FBS (mg%)         | 136.50 | 29.89 | 128.00 | 53.00 | 117.23 | 23.82 | 110.50 | 30.75 | -3.57   | 0.0004 | Significant |
| Duration of DM (years) | 11.50 | 5.38   | 12.00 | 7.00 | 5.63 | 4.29 | 4.00 | 6.00 | -5.27   | <0.0001 | Significant |
| BMI (Kg/m²)       | 27.97 | 2.52   | 28.70 | 4.08 | 24.64 | 1.83 | 24.50 | 2.80 | -6.44   | <0.0001 | Significant |
| Systolic BP (mmHg) | 128.58 | 15.31 | 130.00 | 21.00 | 121.75 | 11.96 | 120.00 | 17.50 | -2.41   | 0.0157 | Significant |
| Diastolic BP (mmHg) | 80.16 | 8.62   | 80.00 | 20.00 | 74.09 | 6.80 | 70.00 | 10.00 | -3.72   | 0.0002 | Significant |
| Serum uric acid (mg%) | 7.13 | 0.54   | 7.20 | 0.43 | 4.33 | 1.43 | 4.55 | 2.50 | -8.81   | <0.0001 | Significant |
| HDL-C (mg%)       | 40.47 | 8.03   | 39.00 | 13.25 | 52.40 | 6.97 | 54.00 | 9.00 | -8.76   | <0.0001 | Significant |
| TG (mg%)          | 174.00 | 18.63 | 178.00 | 21.00 | 140.62 | 24.12 | 133.50 | 37.75 | -6.49   | <0.0001 | Significant |

### Table 12: Comparison of various variables between cases with & without metabolic syndrome + Hyperuricemia.

| Variables         | MS+Hyperuricemia present | MS+Hyperuricemia absent | Unpaired t-test applied |
|-------------------|--------------------------|------------------------|-------------------------|
|                   | Mean | SD     | Median | IQR  | Mean | SD     | Median | IQR  | t-value | p-value | Difference |
| Age (years)       | 63.16 | 7.01   | 62.50 | 9.75 | 55.00 | 9.07   | 53.00 | 12.25 | -4.708  | <0.0001 | Significant |
| FBS (mg%)         | 139.31 | 30.39 | 134.50 | 52.50 | 117.23 | 23.74 | 111.00 | 30.25 | -3.828  | 0.00013 | Significant |
| Duration of DM (years) | 12.66 | 4.54   | 12.50 | 6.50 | 5.64 | 4.36 | 4.00 | 6.25 | -6.379  | <0.0001 | Significant |
| BMI (Kg/m²)       | 28.71 | 1.94   | 28.90 | 3.43 | 24.61 | 1.80 | 24.60 | 2.73 | -7.545  | <0.0001 | Significant |
| Systolic BP (mmHg) | 128.50 | 14.85 | 130.00 | 23.00 | 122.12 | 12.40 | 120.00 | 12.50 | -2.135  | 0.03276 | Significant |
| Diastolic BP (mmHg) | 80.63 | 8.78   | 80.00 | 20.00 | 74.27 | 6.87 | 70.00 | 10.00 | -3.792  | 0.00015 | Significant |
| Serum uric acid (mg%) | 7.13 | 0.53   | 7.20 | 0.48 | 4.47 | 1.53 | 4.60 | 2.65 | -7.907  | <0.0001 | Significant |
| HDL-C (mg%)       | 39.63 | 7.55   | 38.50 | 11.75 | 52.03 | 7.27 | 54.00 | 9.00 | -6.444  | <0.0001 | Significant |
| TG (mg%)          | 176.28 | 17.47 | 178.50 | 20.75 | 141.69 | 24.37 | 135.50 | 41.00 | -6.388  | <0.0001 | Significant |
The patients with both hyperuricemia and metabolic syndrome compared to those without hyperuricemia and metabolic syndrome had higher mean age (63.16 versus 55), higher mean FBS (139.31 versus 117.23), higher mean duration of diabetes (12.66 versus 5.64), higher mean BMI (28.71 versus 24.61), higher systolic BP (128.50 versus 122.12), higher diastolic BP (80.63 vs.74.27), higher TG (176.28 versus 141.69) and lower HDL (39.63 versus 52.03) and these differences are statistically significant for all the variables (p<0.05) (Table 12).

**DISCUSSION**

The present study is conducted on type 2 diabetes patients to know the prevalence of hyperuricemia and metabolic syndrome. The national cholesterol education program’s ATP III report identified the metabolic syndrome as a specific entity deserving more clinical attention. People with the syndrome have risk of developing cardiovascular disease, beyond the risk associated with individual components of the syndrome alone. In this study; metabolic syndrome was defined using the new international diabetes federation (IDF) definition with specific cut off for waist circumference for Indian population.

In the present study, prevalence of metabolic syndrome in type 2 diabetes mellitus is 43.5% using the new international diabetes federation (IDF) definition. The present prevalence is higher than in the study conducted by Ramachandra et al, which found prevalence to be 41% in non-diabetic subjects, Misra A et al noted 29.9%. The higher rate of prevalence in the present study may be due to the study group comprising of only diabetic patients. Eliaesson B et al noted higher prevalence of 77% in diabetic patients. Our study showed higher prevalence of metabolic syndrome in males as compared to females (53.40% versus 33.9%) supported by Marques Vidal P et al (23 versus 12% respective study). Similarly as described above, the higher rate of prevalence in the present study may be due to the study group comprising of only diabetic patients. In this study we found that prevalence of metabolic syndrome increases as duration of diabetes increases. The long standing diabetic mellitus probably allows for more time for other components of MS to develop.

Hyperuricemia is an increasingly common medical problem not only in the advanced countries, but also in the developing countries. It has been described that hyperuricemia is associated with metabolic syndrome components such as obesity, dyslipidemia, hyperglycemia and hypertension. The purpose of our study was to investigate the prevalence of hyperuricemia and the association between uric acid levels and the various metabolic syndrome components in patients with metabolic syndrome. In our study, overall prevalence of hyperuricemia in type 2 diabetes patients is 25.3%. These findings correlate with the study conducted by Anthonia O et al (25%). We found that the incidence of hyperuricemia in males was 33%, which is much higher than that in females (14.5%) that is statistically significant (P<0.05). This result is in line with Conen et al research which had prevalence of 35.1% and 8.7% in males and females respectively. The pathogenic mechanism may be due to estrogen promoting uric acid excretion (Sumino et al.,)20, so it may be more important for men to prevent hyperuricemia. The prevalence of hyperuricemia in those with metabolic syndrome is 47.1% and 7.3% in those without metabolic syndrome (p<0.05). This is statistically significant. These findings are higher than the study conducted by Tuomilehto J et al who found prevalence of 22% and 11% for males and females respectively. In our study, the data indicates that serum triglyceride is markedly associated with hyperuricemia (p<0.05). Conen et al and Schachter et al showed the same results (p<0.05). Hyperuricemia and hypertriglyceridemia are suggested to be associated with insulin resistance syndrome. The association between insulin resistance, hyperuricemia, and hypertriglyceridemia are complicated. This might be expected from the fact that uric acid production is linked to glycolysis and that glycolysis is controlled by insulin. It was shown that uric acid is negatively correlated with serum HDL-C (p<0.05). This finding is consistent with Rho et al research. The mechanisms of this condition may due to the relationship between decreased HDL-C levels and insulin resistance syndrome (Schmidt et al.). In our study, it is found that uric acid concentration is positively correlated with blood pressure and is statistically significant (p<0.05). Similar correlation was suggested by Yoo et al and Feig and Johnson which showed serum uric acid concentration was found to independently correlate with hypertension.

Thus, prevalence of hyperuricemia is significantly higher in patients of metabolic syndrome than patients with type 2 diabetes and general population in India. However the significance of this raised levels in terms of cardiovascular and other complications and also the possible benefit of treatment of hyperuricemia remains to be unanswered and further studies will be needed for the same. The interpretation of the present results is confronted by some limitations. Firstly, the data analysis was restricted to a cross-sectional study. Only a prospective study could confirm the interdependencies of changes in the metabolic syndrome components and serum uric acid levels. Secondly, no serum insulin levels were measured as an index for insulin resistance. As insulin resistance is believed to play a major role in the metabolic syndrome, the inclusion of this variable in our statistical analysis would have been important. On the other hand it is unlikely that adjustment for insulin resistance could significantly influence our strongest association of serum uric acid and triglycerides, nor let disappear the differences found in men and women.
CONCLUSION
Prevalence of metabolic syndrome in patients with type 2 diabetes mellitus is 43.5% and that of hyperuricemia is 23.3%. Prevalence of metabolic syndrome is significantly higher in males than females with diabetes mellitus. Prevalence of metabolic syndrome increases with the duration of diabetes mellitus. Serum uric acid levels are significantly higher in patients of diabetes with metabolic syndrome than those with only diabetes. Prevalence of hyperuricemia is more in males than females with diabetes mellitus. Hyperuricemia is positively correlated with BMI, blood pressure and triglycerides while hyperuricemia is negatively correlated with HDL-C.

ACKNOWLEDGEMENTS
Authors would like to express their sincere thanks to the patients for all their co-operation and help in completing my study.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the institutional ethics committee

REFERENCES
1. Dedwania PC, Gupta R. Management issues in metabolic syndrome. J Assoc Physicians India. 2006;54:797-810.
2. Klein R, Klein BE, Cornoni J, Maready J, Cassel JC, Tyroler HA. Serum uric acid, Georgia. Arch Intern Med. 1973;132:401-10.
3. Bengtsson C, Lappidus L, Stendahal C, Waldenstrom J. Hyperuricemia and risk of cardiovascular disease and over all death. Acta Med Scand. 2002;224:549-55.
4. Nakagawa T, Cirillo P, Sato W, Gersch M, Sautin Y, Roncal C. The conundrum of hyperuricemia, metabolic syndrome and renal disease. Intern Emerg Med. 2008;3(4):313-8.
5. Cai Z, Xu X, Wu X, Zhou C, Li D. Hyperuricemia and Metabolic Syndrome. Asia Pac J Clin Nutr. 2009;18(1):81-7.
6. Chen LY, Jhu WH, Chen ZW, Di HL, Reh JJ. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593-8.
7. Reihmann M, Schutte A, Malan L, Huisman H, and Malan N. Hyperuricemia is an independent factor for metabolic syndrome in a sub-Saharan African population: A factor analysis. Atherosclerosis. 2008;197(2):638-45.
8. Palmer IM, Schutte AE, Huisman HW, Van Rooyen JM, Schutte R, Malan L. A comparison of uric acid levels in black Africans vs. Caucasian women from south Africa. The POWIRS study. Ethnicity and disease. 2007;17:670-6.
9. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome- a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80.
10. Chizynki K, Rozyczka M. Hyperuricemia. Pol Merkur Lekarski (in Polish). 2005;19(113):693-6.
11. Executive summary of third report of NCEP expert panel on detection, evaluation and treatment of high cholesterol in adults. [Expert panel]. JAMA. 2001;285:2486-97.
12. Ramachandran A, Snehalatha G, Satyavathi K. Metabolic syndrome – in Urban Asian Indian Adults – A Population study using Modified ATP III criteria. Diab Res and clin Prac. 2003(60):199-203.
13. Misra A, Wasir JA, Pandey RM. Evaluation of candidate definitions of metabolic syndrome in adult Asian Indians. Diabetes Care. 2005;28(2):398-403.
14. Eliaeson B, Cederholm J, Nilsson P. The gap between guidelines and reality. Type 2 diabetes in a national diabetes register 1996 – 2003. Diabet Med. 2005;22(10):1420-6.
15. Vidal MP, Mazoyer P, Bougarl V. Prevalence of Insulin Resistance syndrome in South Western France and its relationship with inflammatory markers. Diabetes Care. 2002;25(8):1371-7.
16. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 2006;290(3):625-31.
17. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4(1):9.
18. Schachter M. Uric acid and hypertension. Curr Pharm Des. 2004;11(32):4139-43.
19. Anthonia O, Alfred O. Hyperuricemia and metabolic syndrome in type 2 DM. Diabetol Metab Syndr. 2010;2:24.
20. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricemia. Lancet. 1999;354(9179):650.
21. Tuomilehto J, Wolf E, Talyor R, Ram P, King H. Plasma uric acid levels and its association with diabetes mellitus and some biologic parameters in biracial population of Fiji. American journal of epidemiology. 1988;127(2):321-36.
22. Tai ES, Emmanuel SC, Chew SK, Tan BY, Tan CE. Isolated low HDL cholesterol: an insulin-resistant state only in the presence of fasting hypertriglyceridemia. Diabetes. 1999;48(5):1088-92.
23. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Low HDL cholesterol: a component of the metabolic syndrome only in the presence of fasting hypertriglyceridemia in type 2 diabetic patients. Diabetes Metab. 2001;27(1):31-5.
24. Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev. 2000;1(1):47-56.
25. Rho YH, Choi SI, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005;20(6):1029-33.
26. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett R, et al. Clustering of dyslipidemia, hyperuricemia, diabetes and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism. 1996;45(6):699-706.

27. Yoo TW, Sung KC, Shin HS, Kim BI, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J. 2005;69(8):928-33.
28. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247-52.

Cite this article as: Mundhe SA, Mhasde DR. The study of prevalence of hyperuricemia and metabolic syndrome in type 2 diabetes mellitus. Int J Adv Med 2016;3:241-9.